It is evident that TMPRSS2‐ERG, as a biomarker for PCa, shows a clear difference compared to BPH, but PCA3 does not show a significant difference among the PCa, BPH, and control samples. This evidence concerns the gene PCA3 and benign prostatic hyperplasia.